AK152
/ Akesobio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 25, 2025
A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease
(clinicaltrials.gov)
- P1 | N=108 | Not yet recruiting | Sponsor: Akeso
New P1 trial • Alzheimer's Disease • CNS Disorders
November 17, 2025
Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer’s Disease Clinical Trials in China
(PRNewswire-Asia)
- "AK152 is a bispecific antibody that simultaneously targets both Aβ and a receptor highly expressed on the blood-brain barrier. The Aβ-binding arm of AK152 binds to Aβ plaques and exhibits high selectivity for the neurotoxic soluble Aβ oligomers."
New trial • Alzheimer's Disease
1 to 2
Of
2
Go to page
1